Phage display techniques rely on nearly random oligonucleotide sequences inserted into the protein III filament binding protein of an Escherichia coli filamentous phage M13 to generate a library of phage that express more than 10 7 different peptides. Phage that expresses a sequence having high affinity for a specific molecule, cell, or tissue can then be isolated through selective binding and recovery. Selected phage cannot only be used as gene transfer vectors in themselves, but the small peptide epitopes can be sequenced and potentially recombined into the attachment proteins of viral vectors, or used by themselves to target other therapeutic agents and diagnostic imaging radiolabels. Most phage display selections are carried out against purified and / or fixed protein targets, raising concerns as to the relevance of the selected epitopes. We have selected phage from the CMTI library against viable U87 -MG human malignant glioma cells using a derivation of biopanning. The library, which initially contained phage expressing 2Â10 7 different epitope sequences, collapsed after four rounds of selection such that 42% of recovered clones expressed a consensus sequence. Selective binding to viable adherent U87 -MG cells was subsequently demonstrated under physiologic conditions at 167% ( 27% ) unselected phage using a novel, viable enzyme -linked immunosorbent assay technique. In comparison, there was no difference in binding to control 9L rat gliosarcoma, PANC -1 human pancreatic adenocarcinoma, T98 -MG human malignant glioma, or AST -4 human malignant glioma cells of selected compared to unselected phage. Using polymerase chain reaction, the epitope was recovered with flanking unique restriction sites for recombination into a herpes simplex virus type -1 vector. This study demonstrates and discusses optimized methodologies for using phage display to target viable cells. Cancer Gene Therapy ( 2001 ) 8, 506 ± 511
I n the last several years, the first two major products ( Rituxan and Herceptin ), which use monoclonal antibody (MAb) technology to target tumor-selective cell surface receptors, have demonstrated efficacy and entered common clinical practice. Rituxan, which binds to CD -20 overexpressed on lymphomas, not only has intrinsic antitumor efficacy but has been used to target therapeutic radioisotopes. 1, 2 MAb have also been used as diagnostic agents. Prostate -specific membrane antigen ( PSMA ), for example, is highly expressed not only on a number of tumors but also on tumor neovasculature, 3 and radiolabeled MAb against PSMA are now commercially available for diagnostic imaging of prostate tumors. Small peptides that selectively bind tumor cells or tumor neovasculature additionally have the potential to serve as targeted radiolabeled or contrast -tagged imaging or therapeutic agents, as has been demonstrated with 111 Inlabeled octreotide. 4 Within the field of gene therapy, significant work has been conducted, attempting to target vectors to tumor and other cell types through the recombinant addition to viral attachment proteins of MAb or native peptide ligand domains that bind to selectively expressed cell surface receptors ( for review, see Spear 5 and Anderson et al 6 ). Difficulty exists in that even the most truncated forms of antibodies, such as single-chain variable regions ( scFv ) , are large molecules that present significant potential problems for recombination into viral proteins and diffusion into tissue when used alone as therapeutic or diagnostic conjugates. Furthermore, many useful receptors such as PSMA do not have naturally occurring, selective small peptide ligands.
Phage display can provide an additional source of small peptide epitope sequences for targeting. The techni-que initially utilized by Parmley 9 different peptides. Phage expressing a peptide sequence that has high affinity for a specific molecule can then be selected for expansion by binding a fixed target, washing off unbound phage, and eluting bound phage in a process termed biopanning. The DNA sequences coding for the binding peptides are subsequently recovered from the genome of the attached phage. Peptides that target a number of molecules and tissues have been reported. 9, 10 Phage display ±selected epitopes have been used to target pharmaceuticals to tumors. 11 Not only can these epitopes potentially be recombined into the attachment proteins of viral vectors or incorporated into liposomes and DNA conjugates, but Larocca et al 12 and Kassner et al 13 have demonstrated that phage can be used as mammalian gene transfer vectors in themselves and transgene expression with fluorescence -activated cell sorting used as a means of selection.
Limitations of standard biopanning methods include use of a preselected target or fixed cells in standardized incubation solutions, which may not produce epitopes binding the optimal target, if at all, in the context of a living cell under physiologic conditions. Potential difficulties may arise in that cell surface proteins are frequently post -transcriptionally modified specifically to different cell types, including malignancy -specific modifications, then inserted into the cell membrane alone or in conjunction with other cell surface proteins and molecules. Thus, epitopes selected against purified recombinant proteins may not be able to access their targets on living cells due to stereotactic interference by other cell surface molecules, inaccessibility secondary to intramembrane location, conformational changes in the viable cell environment, or acquisition of other associated molecules from the environment. Likewise, in their native environment, cell surface proteins may present different preferable or novel targets or existing targets in a more favorable context. Here we demonstrate the use of living cells and semiphysiologic conditions for the selection and characterization of phage to target U87 -MG glioma cells from a near-random small peptide phage display library, and recovery of the targeting epitope for recombination into other gene therapy vectors.
MATERIALS AND METHODS

Cell lines
U87 -MG human malignant glioma ( ATCC, Rockville, MD ) , T98 -MG human malignant glioma (ATCC ), AST-4 human malignant glioma (cultured from clinical isolate by Francisco S. Pardo ), PANC -1 human pancreatic adenocarcinoma ( ATCC ), or 9L rat malignant glioma cells ( UCSF Brain Tumor Therapy Center, San Francisco, CA ) were cultured in Dulbecco's minimum essential medium ( DMEM ) supplemented with 10% fetal calf serum, 100 U /mL penicillin, 100 g /mL streptomycin (Life Technologies, Grand Island, NY ) at 378C in a 5% CO 2 incubator.
Phage
The CMTI phage display library (Dyax, Cambridge, MA ) consists of M13 E. coli bacteriophage carrying a 90-bp ( 30 aa ) insert into the amino terminus of the pIII coat protein consisting of 23 constant amino acids and seven variable amino acid residues. CMTI or control wild -type M13 phage were propagated with Min A salts added and mixed into XL -1 Blue MRF ( Stratagene, San Diego, CA ) E. coli, which were grown in NZCYM broth with 100 g/mL ampicillin. Similar libraries are commercially available from New England Biolabs (Beverly, MA ).
Biopanning
U87 -MG cells were grown as subconfluent cultures. Cells were rinsed with phosphate -buffered saline (PBS ), harvested with enzyme free dissociation solution ( Versene 0.2 g /L EDTA; Gibco BRL ), washed and centrifuged at 1400Âg in DMEM, and resuspended in 2% casein (blocking agent for nonspecific binding) in PBS. 1Â10 10 pfu of phage from the CMTI phage display library were added to 10 6 cells, and incubated 1 hour while agitating at 378C. Cells were then washed 6Â in 2% casein PBS using centrifugation at 1400Âg to selectively recover cells and bound phage. Phage was eluted with 50 mM glycine and 1.5 M urea pH 2.2 for 1 hour while agitating at room temperature. The solution was neutralized with 0.4 M Tris, pH 8.0, serially diluted, Min A salts added, mixed into XL -1 Blue MRF (Stratagene, San Diego, CA ) E. coli, and plated on NZCYM agar plates with 100 g/ mL ampicillin. Plaques were recovered and expanded in XL -1 Blue MRF. Selection was repeated 4Â with recovered phage serving as the input for the next selection. DNA was extracted from phage recovered after four rounds of selection using a Miniprep kit ( RPM 2 BIO 101, La Jolla, CA ) , and the variable region (random sequence ) was sequenced using flanking primers.
Enzyme -linked immunosorbent assay ( ELISA )
U87 -MG, T98 -MG, AST-4, 9L, or PANC -1 cells were plated at 2.5Â10 4 /well in 96 -well plates. Cells were washed with DMEM, 10% fetal calf serum, 1% penicillin± streptomycin + 20 mM HEPES ( DMEM /HEPES) , pH 7.4. U87 -MG ± selected or unselected control phage was added at 2Â10 10 pfu / well in 200 L DMEM /HEPES and incubated for 1 hour at 378 in 5% CO 2 . Cells were washed 3Â with DMEM /HEPES. Anti-M13 horseradish peroxidase (HRP ) MAb ( 100 L of 0.0002 mg / mL HRP anti -M13 in DMEM /HEPES ) was added and incubated for 1 hour at 378C in 5% CO 2 after quick agitation. Cells were then washed 2Â with DMEM / HEPES and 1Â with PBS, pH 7.4. Tetramethybenzidine ( TMB ) was added and absorbance A 450 ± A 650 read after 5 -minute incubation with an automated plate reader (Molecular Devices ) .
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Epitope recovery
Selected phage colonies were recovered and DNA extracted as above. Synthetic oligonucleotide 51-bp PCR primers matching the variable epitope flanking region, enclosing the variable epitope plus 8 aa to the NH 3 side and 31 aa to the COOH side of flanking constant sequence, and carrying AscI+BstEII (5 H ) and EcoNI + BglII ( 3 H ) restriction sites external to this were used in a PCR reaction to amplify this region. The PCR product was then subcloned into the pTAdv vector (Clontech, Palo Alto, CA ) using the deoxyadenosine tails, sequenced, digested with AscI and EcoNI, and electrophoresed on a 2% agarose gel with ethidium bromide. The epitope bearing AscI and EcoNI fragment was recovered from the gel by electroelution for subsequent recombination into the pCONGAH herpes simplex virus type -1 (HSV-1) amplicon -based targeting system carrying the HSV-1 gC attachment protein with unique AscI and EcoNI restriction sites flanking the heparan sulfate binding domain.
RESULTS
Biopanning
The CMTI library, which initially contained phage expressing 2Â10 7 different epitope sequences, collapsed after four rounds of selection on viable U87 -MG cells, such that with DNA sequencing, 42% ( 5/ 12) of recovered clones expressed the consensus amino acid sequence ±CPKH PLGC, indicating that phage bearing this sequence are preferentially retained on U87 -MG cells (Fig 1 ) . Three of these colonies carried the specific sequence MCPKHPLGC and two carried LCPKHPLGC, leaving in question the importance of the first residue as to whether any amino acid would suffice or only M and L.
ELISA
One of the phage clones (CMTI#2 ) bearing the most common consensus sequence (MCPKHPLGC ) was arbitrarily chosen for further characterization. Selective binding to viable U87 -MG cells was seen under physiologic conditions ( pH 7.4, DMEM 10% serum, 378C) at 167% ( 27% ) unselected phage using a viable adherent phase ELISA. In comparison, there was no relative difference in binding to control T98 -MG human glioblastoma, AST-4 human malignant glioma, or 9L rat gliosarcoma and PANC -1 human pancreatic adenocarcinoma cells, which would not be expected to present human malignancy or glial-related antigens, respectively ( Fig 2) .
Epitope recovery
For the CMTI#2 clone, DNA sequencing confirmed recovery of the variable epitope sequence, flanking scaffold sequences, and restriction sites. Digestion with AscI and EcoNI produced a fragment of the appropriate size to allow recombination into the binding region of the HSV-1 gC attachment protein carried by an HSV-1 amplicon vector targeting system using the selective restriction method as described by Spear. 
DISCUSSION
The above results indicate that viable cell selection allows for isolation of phage bearing a specific sequence that preferentially binds to viable target cells as demonstrated by sequence collapse and ELISA, that viable solid -phase (vspELISA) allows quantification of phage binding to viable cells under physiologic conditions, and that an epitope can be easily recovered for recombination into other gene therapy vectors. The relatively modest increase in absolute binding ( 167% ) and continued high -level binding to nontarget cells, as demonstrated by ELISA, seem to indicate that this method maybe insufficient for effective vector targeting. However, one must realize that this difference is in the context of an intact phage particle. Significant background binding of control phage and variable binding to nontarget cells are of concern for reducing the intrinsic sensitivity of this method. Although there is clearly enough differential to collapse the library to a single preferred consensus sequence, steps including selection under more physiologic conditions or with preliminary subtractive selection on nontarget cells to remove phage with high nonselective binding should be considered to improve the binding differential. The inclusion of 1 mM phenylmethylsulfonyl fluoride and 2.5 mM EDTA has also been used with the intent of reducing nonspecific cell binding, 15 and could be further incorporated into the ELISA incubation solutions to improve sensitivity. Some or most of the nonselective bindings may originate in other phage proteins, and thus may not be of issue if the epitope alone is transferred to other vectors or to relatively inert therapeutic and diagnostic agents. In that the selected epitope has demonstrated the ability to overcome these hurdles to some degree indicates its potential value. Thus, a reasonable next step would be to evaluate binding of synthetic polypeptide epitopes alone to cells. Furthermore, if used to target a replication -competent or replication -conditional gene therapy vector, such as hrR3 16 or rRp450, 17 even a small difference in binding and transduction may be amplified by continued preferential proliferation within the tumor.
Cell lines were chosen in this study to discriminate between phage, which may bind to receptors found selectively on glioma cells ( U87 -MG, T98 -MG, AST-4 and 9L ), malignant cells ( all ), human cells ( U87 -MG, AST-4, T98 -MG, and PANC -1) , or human malignant glioma cells ( U87 -MG, T98 -MG, and AST-4 ). Additional cell lines and normal tissue explants (e.g., glial cell ) would be used to discriminate between mesenchymal malignancy or glial cell ± selective phage. Frequent selection of epitopes binding highly expressed pan-human antigens would be an expected and unwanted outcome of most similar biopanning protocols. In the selection of nonsmall cell lung carcinoma ± specific phage carrying antibody scFv, Ridgway et al 15 have reported use of an initial subtractive biopanning using nontarget or``normal'' tissue cells to remove phage targeting nonselective epitopes in a fluid -phase selection / fluid -phase ELISA system. Lu and Sloan 18 have used alternating contaminating antigens or blocking agents through successive steps of a fixed peptide biopanning to avoid selecting phage dependent on extraneous interactions.
Likewise, alternating between different cell lines of a tumor type may improve the probability of isolating phage selective to that tumor type as opposed to cell line ± specific or ± selective antigens. During biopanning, we currently use a preliminary subtractive selection round on nontarget cells such as normal fibroblast or glial cell cultures to remove phage with high nonselective binding, and run an alternating cell line pattern in parallel to a single line. The normal tissue for such a subtractive selection should be chosen carefully so as not to overly limit binding ranges of the selected epitopes from nonvital tissues that may share tumor-selective epitopes.
Another potential difficulty rests in the degree to which the above conditions mimic the in vivo environment derivative epitopes would be used in. Characteristics of the biopanning media, such as ionic strength and pH, have been shown to directly affect the outcome of phage selected, 19 but would also be expected to affect the targets cells and thus their presentation of cell surface proteins. Certainly, in future protocols, modifications could be made to more carefully duplicate in vivo human or murine physiology. As matrix adherence in confluence with neighboring cells is the native state of solid tumor cells and can change the antigenic repertoire of a cell, we recommend the use of confluent attached cells as opposed to artificially suspended cells. In a related issue, cleavage of cell surface proteins could be caused through the use of trypsin in harvesting. Thus, we use EDTA to harvest cells and wait 2 days after plating to allow for recovery of any alterations in antigen repertoire prior to assay. The use of actual human or murine blood products or components thereof with explanted tumor tissue would be a potential extension of this concept. This is, however, fraught with potential problems involving safety, cost, storage, stability, and reproducibility. Additionally, such nonstandard reagents may interfere with the conduct of the protocol. As it is, the final wash with PBS in the above protocol was necessary to remove traces of media, which interfere with TMB conversion and reading. Additional ELISA methods that were investigated with less evaluable results included other nonphysiologic buffers, casein as a blocking agent, incubation with suspended and/ or trypsinized cells with centrifugation, and aliquoting into 96-well plates. Of course, the optimal situation would be selection and assay of phage epitopes in vivo in the context of the therapeutic target. This has been done in pioneering work by Pasqualini and Ruoslahti 10 who injected phage display libraries into mice intravenously, then harvested the brain and kidney and recovered phage therefrom, subsequently demonstrating phage and specific epitope sequences that preferentially targeted brain and kidney. Other groups have since attempted this with implanted tumors, with as of yet no reported success. Numerous problems may arise in such in vivo models with regard to properties of the phage, particularly size ( 1000 nm in length ), possible retention in reticuloendothelial organs, and ability to access to tumor antigens through the vasculature (although it is expected that tumor neovasculature ± selective antigens would be available, and smaller phage species such as T7 can be used ).
Cancer Gene Therapy, Vol 8, No 7, 2001 SPEAR, BREAKEFIELD, BELTZER, ET AL: SMALL PEPTIDE PHAGE DISPLAY EPITOPES Common mammalian vectors such as HSV-1 and adenovirus have significant potential advantages over phage or polypeptide epitope-coupled vectors, including in situ replication and spread, transduction efficiency, large transgene capacity, and flexibility to have a broad array of vector characteristics recombinantly altered depending on the intended use. As described above, subsequent to identification of targeting phage display epitopes, flanking PCR primers with cohesive ends matching the intended insert site of a viral protein can be designed to generate and transfer selected targeting epitopes to other vectors. This method actually allows for the potential recovery and transfer of multiple epitopes from a selected library simultaneously without cloning or sequencing, and subsequent segregated or combined use. Alternatively, the epitope sequence can be generated by synthetic oligonucleotides in either one molecule for a small epitope ( < 35 aa ) or multiple overlapping molecules for larger epitopes. The disadvantage to this method is that new oligonucleotides must be synthesized for each epitope after cloning and sequencing. It remains to be demonstrated how such epitopes will function in a new protein environment, but we have followed a practice of including the entire designed epitope plus approximately 5± 10 aa of additional flanking native phage``scaffolding'' sequence to try to ensure that the immediate conformational environment of the epitope is not significantly changed, realizing that in practice, even distant or noncontiguous protein and nonprotein moieties may contribute to effective epitope binding, and that this dependence would likely vary from epitope to epitope. Arap et al 11 have used as little as 5 aa to target doxorubicin conjugates, and thus evidenced that the entire variable region may not even be needed. Evaluation of binding of a synthetic polypeptide epitope alone with variable amounts of surrounding scaffold would answer this question for the specific epitope. Certainly, many libraries use a variable region with as few as 7 aa sequential variables, and thus, these could be recovered and tested with oligonucleotides as short as 21 bp plus restriction sites. The epitopes could further be synthesized alone or as fusion proteins from expression vectors and used to target other therapeutic or diagnostic agents with concomitant advantages relevant to their small size. Additional utility can be gained as the targeted receptor can be identified by antigen expression cloning, 15 thus allowing the development of additional therapeutic strategies related to any novel receptor identified, as well as identification of patients that would most benefit from targeting the specified receptor through techniques such as immunohistochemistry and expression array analysis. A potentially valuable extension of phage display technology that we are currently investigating is the synthesis random peptide libraries within the context of the attachment proteins of the common viral vectors. This has the advantage of beginning with the selected epitope in its final environment and thus avoiding the resource utilization and potential difficulties of translation into a new protein.
There are, however, barriers to accomplishing this in terms of obtaining sufficient library diversity with a realistic amount of resources given current vector manipulation methodologies. As noted in the reviews cited above, 5, 6 a number of binding domains have been inserted into the attachment proteins of viral vectors, and thus, the methodology described herein provides a flexible means of greatly expanding upon the potential of vector targeting, but with a number of technical issues yet to be investigated to optimize efficacy.
CONCLUSION
There are significant potential advantages in utilizing viable cells in a physiologic environment for selection and evaluation compared to other described techniques in terms of presenting an antigenic repertoire that is as similar as possible to that encountered in vivo. For the optimal methodology, we would additionally recommend an initial subtractive panning step on a relevant nonmalignant cell culture and alternating target cell lines during biopanning. Small peptide epitopes provide for ease of subsequent manipulation and good tissue distribution as conjugates. The PCR method of epitope recovery and transfer also presents significant advantages in terms of efficiency and flexibility. When minimized, the overall methodology offers a relatively rapid and efficient means of epitope selection, characterization, and recovery for further use.
